Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 1/20 | 0.46 |
| ▸ | TK1 | P04183 | 3/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16307200 | 1.00 | PYGM (0.46) | PYGMTK1P2RY6P2RY14TSHR | |
| SCHEMBL13976532 | 1.00 | PYGM (0.46) | PYGMTK1P2RY6P2RY14TSHR | |
| SCHEMBL12840822 | 0.90 | PYGM (0.50) | PYGMTK1P2RY6P2RY14BCHE | |
| SCHEMBL16307368 | 0.90 | PYGM (0.50) | PYGMTK1P2RY6P2RY14BCHE | |
| SCHEMBL13978280 | 0.90 | PYGM (0.50) | PYGMTK1P2RY6P2RY14BCHE | |
| SCHEMBL24359129 | 0.90 | PYGM (0.50) | PYGMTK1P2RY6P2RY14BCHE | |
| SCHEMBL13976551 | 0.90 | PYGM (0.50) | PYGMTK1P2RY6P2RY14BCHE | |
| SCHEMBL13976530 | 0.90 | PYGM (0.50) | PYGMTK1P2RY6P2RY14BCHE | |
| SCHEMBL16307197 | 0.90 | PYGM (0.50) | PYGMTK1P2RY6P2RY14BCHE | |
| SCHEMBL14702153 | 0.89 | PYGM (0.41) | PYGMTK1P2RY6P2RY14TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912318-B2 | Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting nucleic acids | UNIVERSITY OF IDAHO (US) | 2014-12-16 | — | — | US | disclosed |
| US-8518908-B2 | Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting of nucleic acids | UNIVERSITY OF IDAHO (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120295862-A1 | NUCLEOBASE-FUNCTIONALIZED CONFORMATIONALLY RESTRICTED NUCLEOTIDES AND OLIGONUCLEOTIDES FOR TARGETING OF NUCLEIC ACIDS | The Univeristy of Idaho | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295862-A1 | NUCLEOBASE-FUNCTIONALIZED CONFORMATIONALLY RESTRICTED NUCLEOTIDES AND OLIGONUCLEOTIDES FOR TARGETING OF NUCLEIC ACIDS | NT5C3B, UNG, NT5C2 | PYGM 3680/4885TK1 240/4885P2RY6 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.